(CercleFinance.com) – AstraZeneca presented positive data on its three main cancer drugs on Sunday at the European Society for Medical Oncology (ESMO) congress, which is currently being held in Paris.
The biopharmaceutical group has notably unveiled the detailed results of a phase II study on Enhertu, the conjugate antibody it is developing with the Japanese Daiichi Sankyo, having shown a ‘significant’ response from the tumor in patients suffering from a unresectable and/or metastatic non-small cell lung cancer.
Also at ESMO, the company announced phase III results on Tagrisso showing a significant clinical improvement in disease-free survival in patients with non-small cell lung cancer. an early stage.
Finally, phase III data with Imfinzi showed a marked improvement in overall survival in patients with stage 4 non-small cell lung cancer.
Listed on the London Stock Exchange, the AstraZeneca share changed little (+0.4%) Monday morning following all these announcements.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
